SCHEMBL7050463

SCHEMBL7050463

NS(=O)(=O)c1ccccc1NC(=O)c1ccc([N+](=O)[O-])c(OCc2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 4/20 0.61
MAX P61244 3/20 0.61
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
AKR1C1 Q04828 1/20 0.56
MAPT P10636 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
CYP19A1 P11511 1/20 0.48
GAA P10253 1/20 0.48
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
AR P10275 1/20 0.46
PELP1 Q8IZL8 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
EP300 Q09472 1/20 0.46
HIF1A Q16665 1/20 0.46
PTGES2 Q9H7Z7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7080413 0.84 MYC (0.55) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL12068720 0.83 MYC (0.85) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL7081540 0.81 AKR1C3 (0.58) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL7048363 0.78 MAOB (0.59) MAPTMEN1KMT2AGAACA1
SCHEMBL7049305 0.78 SMPD1 (0.60) MEN1KMT2AGAASMN1; SMN2PTGES2
SCHEMBL23628923 0.77 MYC (0.56) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL30082870 0.77 MYC (0.67) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL528177 0.77 MYC (0.67) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL3109633 0.77 BRD4 (0.64) MYCMAXAKR1C3AKR1C2AKR1C1
SCHEMBL14106122 0.77 CA1 (0.56) AKR1C2AKR1C1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191323-A1 Hypoglycemic agent AJINOMOTO CO., INC. (JP) 2003-10-09 US disclosed
US-20030162818-A1 Acylsulfonamide derivative AJINOMOTO CO. INC. (JP) 2003-08-28 US disclosed
US-6555584-B1 Acetyl-coa carboxylase inhibitors AJINOMOTO CO., INC. (JP) 2003-04-29 US disclosed
EP-1300142-A1 HYPOGLYCEMICS Ajinomoto Co., Inc. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162818-A1 Acylsulfonamide derivative ACSS2, ACACA, FASN MYC 1649/4885MAX 4277/4885AKR1C3 228/4885
US-20030191323-A1 Hypoglycemic agent GPR119, IAPP, SLC5A2 MYC 4511/4885MAX 4701/4885AKR1C3 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.